Dihydromyricetin Ameliorates Inflammation-Induced Insulin Resistance via Phospholipase C-CaMKK-AMPK Signal Pathway

Lianjie Hou,1,2 Fangyi Jiang,1 Bo Huang,1 Weijie Zheng,1 Yufei Jiang,1 Gengyuan Cai,1 Dewu Liu,1 Ching Yuan Hu,3 and Chong Wang1

1Guangdong Provincial Key Lab of Agro-Animal Genomics and Molecular Breeding, National Engineering Research Center for Breeding Swine Industry, College of Animal Science, South China Agricultural University, China
2The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan City People’s Hospital, Qingyuan, 511518 Guangdong, China
3Department of Human Nutrition, Food and Animal Sciences, College of Tropical Agriculture and Human Resources, University of Hawaii at Manoa, USA

Correspondence should be addressed to Chong Wang; betty@scau.edu.cn

Received 15 July 2020; Revised 7 August 2021; Accepted 26 August 2021; Published 5 October 2021

Academic Editor: Silvana Hrelia

Copyright © 2021 Lianjie Hou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Patients with metabolic syndrome have a higher risk of type II diabetes and cardiovascular disease. The metabolic syndrome has become an urgent public health problem. Insulin resistance is the common pathophysiological basis of metabolic syndrome. The higher incidence of insulin resistance in obese groups is due to increased levels of inflammatory factors during obesity. Therefore, developing a therapeutic strategy for insulin resistance has great significance for the treatment of the metabolic syndrome. Dihydromyricetin, as a bioactive polyphenol, has been used for anti-inflammatory, antitumor, and improving insulin sensitivity. However, the target of DHM and molecular mechanism of DHM for preventing inflammation-induced insulin resistance is still unclear. In this study, we first confirmed the role of dihydromyricetin in inflammation-induced insulin resistance in vivo and in vitro. Then, we demonstrated that dihydromyricetin resisted inflammation-induced insulin resistance by activating Ca2+-CaMKK-AMPK using signal pathway blockers, Ca2+ probes, and immunofluorescence. Finally, we clarified that dihydromyricetin activated Ca2+-CaMKK-AMPK signaling pathway by interacting with the phospholipase C (PLC), its target protein, using drug affinity responsive target stability (DARTS) assay. Our results not only demonstrated that dihydromyricetin resisted inflammation-induced insulin resistance via the PLC-CaMKK-AMPK signal pathway but also discovered that the target protein of dihydromyricetin is the PLC. Our results provided experimental data for the development of dihydromyricetin as a functional food and new therapeutic strategies for treating or preventing PLC.

1. Background

With the changes in modern lifestyles, such as excessive energy intake, lack of regular exercise, and accelerated life rhythm, the incidence of metabolic syndrome-related diseases has increased year by year [1]. Metabolic syndrome is defined as a disorder of energy use and storage. This syndrome is characterized by central obesity, dyslipidemia, raised blood pressure, and high blood glucose levels [2]. Although the prevalence of metabolic syndrome varies globally based on race, age, and gender, the incidence rate is as high as 10-84%. Patients with metabolic syndrome have a higher risk of type II diabetes and cardiovascular disease [3]. Therefore, the metabolic syndrome has become an urgent public health problem.

Insulin resistance is the common pathophysiological basis of metabolic syndrome [4]. Insulin resistance is defined as a decrease in insulin sensitivity in the major insulin target organs such as adipose tissue, liver, and muscle. Insulin resistance is one of the significant characteristics of type II diabetes [5]. Studies have shown that insulin resistance has become a high-risk factor for chronic diseases such as type II diabetes, nonalcoholic fatty liver disease, cardiovascular disease, and even Alzheimer’s disease [6]. Therefore,
developing a therapeutic strategy for insulin resistance has great significance for the treatment of the metabolic syndrome.

The increase of proinflammatory cytokines, such as IL-1β, IL-6, TNFα, and MCP1, in adipose tissue during obesity, is the direct cause of insulin resistance [7]. Among the proinflammatory cytokines that induce insulin resistance, tumor necrosis factor α (TNFα) is the most representative one. Inflammatory cytokines impair insulin signaling and trigger insulin resistance. The main pathways of inflammation-induced insulin resistance include nuclear factor-kappa B (NF-κB) signaling pathway and c-Jun NH2-terminal kinase (JNK) signaling pathway [8]. NF-κB inhibits the activation of phosphatidylinositol 3-kinase- (PI3K-) protein kinase B (AKT) signaling pathway by inhibiting phosphorylation of insulin receptor substrate (IRS), resulting in insulin resistance [9]. JNK inhibits the PI3K-AKT signaling pathway by downregulating the expression and phosphorylation of the IRS, resulting in insulin resistance [10]. Therefore, inhibiting chronic inflammation is a promising therapeutic strategy to improve insulin resistance.

Dihydromyricetin (DHM), also known as ampelopsin, is the main bioactive polypHENol in rattan tea. Rattan tea has been used for anti-inflammatory in China and other Asian countries for several centuries [11]. DHM exerted its anti-inflammatory effect in rats through suppressing NF-κB signaling in macrophage [12]. DHM concentration dependently increased the glucose uptake in insulin-resistant 3T3-L1 adipocytes induced by dexamethasone [13]. DHM also improved skeletal muscle insulin sensitivity by partially inducing autophagy via activation of the AMPK-PGC-1α signaling pathway [14]. DHM attenuated metabolic syndrome and improves insulin sensitivity by upregulating phosphorylation of IRS in db/db mice [15]. Currently, most DHM-related research reported that DHM functions depend on its activation of AMPK; but AMPK is not the direct target of DHM in cells, and the target of DHM in cells is still unclear. To our knowledge, there is no published paper demonstrated the DHM effect on inflammation-induced insulin resistance.

In this study, we used high-fat diet (HFD) feeding to induce insulin resistance in vivo. Gavage DHM was used to determine DHM function in reducing the level of inflammation and inhibiting insulin resistance in obese mice. 3T3-L1 cells were treated with TNFα as a model of inflammation-induced insulin resistance in vitro. We have elucidated the molecular mechanism of DHM for preventing inflammation-induced insulin resistance in 3T3-L1 using immunofluorescence, signal pathway blocking, and drug affinity responsive target stability (DARTS) assay. Our results provided not only experimental data for the development of DHM as a functional food additive but also offered a new therapeutic strategy for treating insulin resistance.

2. Materials and Methods

2.1. Animal Experiment. Thirty-six 18-day-old specific pathogen free (SPF) healthy male C57B/L6 mice were purchased from the Animal Experiment Center of Guangdong Province of the People’s Republic of China. All experimental protocols and methods were approved by the College of Animal Science, South China Agricultural University.

2.2. Oral Glucose Tolerance Test. After fasting for about 12 hours, the blood glucose of the mice was measured by ACCU-CHEK Mobile (Roche, Mannheim, Germany). Then, the mice were given oral administration of glucose (1.0 g/kg) solution. After 30, 60, 90, 120, and 180 min, blood samples were collected via the tail vein for the measurement of blood glucose levels.

2.3. Hematoxylin-Eosin Staining (H&E). The mouse adipose tissue was fixed in 4% formaldehyde (DaMao, Tianjin, China) at room temperature for 48 h. The method used for the H&E staining has been described previously [16]. The adipocyte area is calculated by the Image J software.

2.4. Body Composition Analysis. Fat mass, lean mass, and body composition were determined using a nuclear magnetic resonance system according to the manufacturer’s instruction (Body Composition Analyzer MiniQMR23-060H-I, Niumag Corporation, Shanghai, China).

2.5. 3T3-L1 Culture and Inflammatory Induce 3T3-L1 Insulin Resistance. The 3T3-L1 cell line used in this study was purchased from American Type Culture Collection (ATCC, VA, USA). 3T3-L1 was cultured in DMEM/High Glucose (HyClone, PA, USA) with 10% Fetal Bovine Serum (Gibco, NY, USA). 3T3-L1 cells were seeded in 24-well plates (4 x 10^5/cm^2). After 24 h, we treated the 3T3-L1 with TNFα (MedChemExpress, Monmouth Junction, USA) at the concentration of 1 ng/mL for 5 days to induce 3T3-L1 insulin resistance. We treated 3T3-L1 cells with TNFα and DHM (1 μM, Sigma Chemical Inc., Louis, MO, USA) for 5 days to demonstrate DHM ameliorated inflammation-induced insulin resistance. We treated 3T3-L1 cells with TNFα, DHM, and Compound C (the AMPK inhibitor, 5 μM, MedChemExpress, Monmouth Junction, USA) for 5 days to demonstrate DHM ameliorated inflammation-induced insulin resistance through AMPK. We treated 3T3-L1 cells with TNFα, DHM,
and STO-609 (the CaMKK inhibitor, 10 ng/mL, MedChemExpress, Monmouth Junction, USA) for 5 days to demonstrate DHM ameliorated inflammation-induced insulin resistance through CaMKK. We treated 3T3-L1 cells with TNFα, DHM, and U73122 (1 μM, MedChemExpress, Monmouth Junction, USA) for 5 days to demonstrate DHM ameliorated inflammation-induced insulin resistance through the PLC-IP3 receptor pathway.

2.6. Glucose Uptake Assay. Five days after treatments, the glucose uptake was assayed by 2-NBDG (MedChemExpress, Tokyo, Japan) was used to observe fluorescence. Fluorescent data were acquired at excitation and emission wavelengths of 490 and intensity at 525 nm.

2.7. Methyl Thiazolyl Diphenyl-Tetrazolium Bromide (MTT). 3T3-L1 cells were seeded in 96-well plates at a density of 3 × 10^4/cm². After 12 h culture, 15 μL of treatments (TNF or DHM) with different concentrations was added to the cells for another 24 h of incubation. MTT was performed according to the manufacturer’s protocol (M1020-500T, Solarbio, Beijing, China).

2.8. Calcium (Ca^{2+}) Imaging. Ca^{2+} was measured by a Ca^{2+} fluorescent probe fluo-4-AM kit following the manufacturer’s instructions. 3T3-L1 cells were incubated with ryanodine (100 nM, MedChemExpress, Monmouth Junction, USA) or U73122 (1 μM, MedChemExpress, Monmouth Junction, USA) for 1 h to block the endoplasmic reticulum Ca^{2+} channel. Then, the cells were washed 3 times with Hank’s Balanced Salt Solution and incubated with 10 μM fluo-4-AM at 37°C for 1 h. After incubation, cells were then rewarshed 3 times. Nikon Eclipse Ti-s microscopy (Nikon, Tokyo, Japan) was used to observe fluorescence. Fluorescent data were acquired after excitation at 490 nm and intensity at 525 nm.

2.9. RNA Extraction and PCR Analysis. Methods used for the RNA extraction and PCR analysis have been described previously [17]. The relative expression of mRNAs was normalized with β-actin levels using the 2^[-ΔΔCt] method. 2^[-ΔΔCt] is defined as the ratio of the relative mRNA level between the experimental group and the control group. Primers were designed using Primer Premier 5 based on sequences of mouse genes obtained from NCBI. All the primers used in this study are shown in Table 1.

2.10. Western Blot Analysis. The method used for the western blot analysis has been described previously [18]. Band intensities were quantified by the Image J software. The antibodies and their dilutions used in this study are listed in Table 2.

2.11. Drug Affinity Responsive Target Stability (DARTS) Assay. DARTS experiments for identifying the targets of DHM were performed as previously reported [19]. In brief, 3T3-L1 cells were lysed and treated with DHM (10 nM or 1 μM) for 1 h at room temperature. Then, the mixture was digested with 0.01% protease for 30 min at room temperature. The digestion was stopped by directly add 5×SDS-PAGE loading buffer and inactivation by boiling 5 min. Protein samples were separated with 8%-15% SDS-polyacrylamide gels and analyzed by Coomassie blue staining and western blotting.

2.12. Statistical Analysis. All data are expressed as the mean ± standard error of the mean (SEM) of three independent experiments. Our data is a normal distribution, and the homogeneity of data between each treatment group is equal under the SPSS analysis. In Figures 1(d), 2(c), 3(b), 4(e) and 4(h), and 5(f), the unpaired Student’s t-test was used for p value calculations, where * represents p < 0.05 and ** represents p < 0.01. Significant differences among groups (≥3) were determined by one-way ANOVA (SPSS v18.0, IBM Knowledge Center, Chicago, IL, USA). Multiple comparisons between the groups were performed using the S-N-K method. Any two bars with different letters indicate that these two groups are statistically significantly different (p < 0.05).

3. Results

3.1. DHM Reduced Fat Accumulation and Inflammation in HFD-Induced Obese Mice. Compared with the HFD group, HFD not only increased energy intake and body weight gain in mice (Figures 6(a) and 6(b)), but HFD also increased fat mass (Figures 6(c)), indicating the HFD-induced obese mouse model was constructed successfully. Compared with
the HFD group, DHM did not affect energy intake and body weight gain (Figures 6(a) and 6(b)), but DHM prevented the increase of fat mass caused by HFD (Figure 6(c)). Both adipose tissue weight and adipose tissue index (percentages of iWAT weight/body weight or eWAT weight/body weight) were increased in HFD-induced obese mice compared with the control group (Figures 6(d) and 6(e) and Figure S1B). DHM reversed the HFD-induced eWAT and iWAT hypertrophy (Figures 6(d) and 6(e) and Figure S1B). We found HFD increased the area of adipocytes in iWAT and eWAT, while DHM inhibited the hypertrophy of adipocytes caused by HFD, based on the H&E results (Figure 6(f) and Figure S1B). For the energy metabolism-related parameters, HFD increased the levels of glucose, insulin, total triglycerides, total cholesterol, and free fatty acids in serum. DHM alleviated the increase of energy metabolism-related parameters in serum caused by HFD (Figure 6(g)). Since obesity is always accompanied by low-level inflammation, we also measured the level of the inflammatory cytokines in the serum. HFD induced a higher level of IL-1β, IL-6, TNFα, and MCP1 in obese mice, as measured by ELISA. DHM reduced the increase in the HFD-induced inflammatory cytokines in the serum (Figure 6(h)). These results indicate that DHM reduced fat accumulation and inflammation in HFD-induced obese mice.

3.2. DHM Ameliorated Insulin Resistance Induced by Inflammation in HFD Mice. To investigate whether DHM ameliorated insulin resistance induced by inflammation, we measured the level of inflammatory cytokines in adipose tissue and insulin sensitivity in mice. ELISA results showed that HFD caused an increase in inflammatory cytokines IL-1β, IL-6, TNFα, and MCP1 in adipose tissue, while DHM reduced the level of adipose tissue inflammatory cytokines induced by HFD (Figure 7(a)). Through the oral glucose tolerance test, we found that the glucose clearance ability was decreased in the HFD-induced obese mice, while DHM enhanced the ability of glucose clearance in the HFD-fed mice (Figure 7(b)). qPCR and western blot results also showed that AMPK, an adipose tissue energy metabolism sensor, was inhibited in HFD-induced obese mice (Figures 7(c) and 7(d) and Figure S2). HFD-induced obesity activated the expression of NF-κB and JNK. NF-κB and JNK, in turn, inhibited the activation of IRS-1 and AKT, indicating that HFD induced insulin resistance (Figures 7(c) and 7(d) and Figure S2). The insulin resistance, subsequently, inhibited the expression of GLUT4, a transporter for glucose uptake (Figures 7(c) and 7(d) and Figure S2). However, DHM activated AMPK and inhibited NF-κB and JNK induced by HFD. DHM reversed the inhibition on IRS-1 and AKT induced by HFD and finally increased GLUT4 expression (Figures 7(c) and 7(d) and Figure S2). These results indicate that DHM ameliorated inflammatory-induced insulin resistance in HFD mice.

3.3. TNFα Induced Inflammatory Response and Insulin Resistance in 3T3-L1 Cells. We constructed a cellular model of TNFα-induced insulin resistance in 3T3-L1 cells to establish the mechanism of DHM in relieving HFD-induced inflammation and insulin resistance. TNFα, less than 50 ng/mL, did not damage cell viability based on the result of MTT assay (Figure 1(a)). To simulate the low-level

Table 2: The details of antibodies used in this study.

| Primary antibody | Clone       | Company | Catalog No. | Dilution |
|------------------|-------------|---------|-------------|----------|
| PLC              | Polyclonal  | Abcam   | Ab41433     | 1:2000   |
| CaMKK            | Polyclonal  | Abbkine | ABP53531    | 1:1000   |
| p-CaMKK          | Polyclonal  | Affinit | AF4487      | 1:1000   |
| LKB1             | Polyclonal  | Bios    | bs-3948R    | 1:2000   |
| AMPK             | Polyclonal  | Abbkine | ABP50650    | 1:1000   |
| p-AMPK           | Polyclonal  | Abbkine | ABP50452    | 1:1000   |
| JNK              | Polyclonal  | ZEN BIO | 380556      | 1:2000   |
| NF-κB            | Polyclonal  | Bios    | bsm-33117M  | 1:5000   |
| p-NF-κB          | Polyclonal  | Bios    | bs-3485R    | 1:500    |
| IRS-1            | Polyclonal  | Abcam   | 341420      | 1:1000   |
| p-IRS-1          | Polyclonal  | Abcam   | Ab3690      | 1:2000   |
| AKT              | Monoclonal  | CST     | # 9272S     | 1:2000   |
| p-AKT            | Monoclonal  | CST     | # 4058S     | 1:2000   |
| PI3K             | Polyclonal  | ZEN BIO | 385369      | 1:1000   |
| p-PI3K           | Polyclonal  | ZEN BIO | 530854      | 1:1000   |
| GLUT4            | Polyclonal  | Abcam   | ab109313    | 1:2000   |
| β-Actin          | Monoclonal  | Bioworld| BS6007M     | 1:5000   |
| Secondary antibody | Conjugate | Company | Catalog No. | Dilution |
| Goat anti-rabbit IgG | HRP | Bios    | bs-0295G    | 1:5000   |
| Goat anti-mouse IgG | HRP | Bioworld| BS12478     | 1:5000   |
Figure 1: TNFα induced inflammatory response and insulin resistance in 3T3-L1 cells. (a) The optimal TNFα concentration used in 3T3-L1 experiments was determined by MTT. (b) The glucose uptake test confirmed that TNFα induced insulin resistance in 3T3-L1 cells. (c) Quantitative analysis of fluorescence intensity in (b) using the Image J software. (d) mRNA level of inflammation-induced insulin resistance-related genes was determined by qPCR. (e) The protein level of inflammation-induced insulin resistance-related genes was measured by WB. "p-" before the gene name means phosphorylated form. N = 6, *p < 0.05, and **p < 0.01. Any two bars with different letters indicate that these two groups are statistically significantly different (p < 0.05). Magnification was 100x. The scale bar on the photomicrographs represents 50 μm.
Figure 2: DHM (1 μM) ameliorated the inflammatory-induced insulin resistance. (a) The optimal DHM concentration used in 3T3-L1 was determined by MTT. (b) The glucose uptake test confirmed that TNFα induced insulin resistance in 3T3-L1 cells. (c) Quantitative analysis of fluorescence intensity in (b) using the Image J software. (d) The effect of DHM on the mRNA level of the inflammatory-induced insulin resistance-related genes was measured by qPCR. (e) The effect of DHM on the protein level of the inflammatory-induced insulin resistance-related genes was detected by WB. "p-" before the gene name means phosphorylated form. N = 6, **p < 0.01. Any two bars with different letters indicate that these two groups are statistically significantly different (p < 0.05). Magnification was 100x. The scale bar on the photomicrographs represents 50 μm.
inflammatory response during obesity, we selected the TNFα concentration of 1 ng/mL for five days in subsequent experiments. After five days of TNFα treatment, insulin stimulation did not increase glucose uptake in 3T3-L1 cells, and the cells developed an insulin resistance phenotype (Figures 1(b) and 1(c)). qPCR and western blot results also showed that AMPK was inhibited after TNFα treatment (Figures 1(d) and 1(e) and Figure S3). TNFα treatment activated the expression of NF-κB and JNK (Figures 1(d) and 1(e) and Figure S3). NF-κB and JNK, they, in turn, inhibited IRS-1 and AKT, indicating that TNFα induced insulin resistance (Figures 1(d) and 1(e) and Figure S3). The insulin resistance, subsequently, inhibited the expression of GLUT4 (Figures 1(d) and 1(e) and Figure S3). Thus, these results suggest that TNFα activated the inflammatory response and induced insulin resistance.

**Figure 3:** DHM (1 μM) ameliorated inflammation-induced insulin resistance through AMPK. (a) DHM alleviated TNFα-induced insulin resistance was dependent on AMPK, as shown by the glucose uptake test. (b) Quantitative analysis of fluorescence intensity in (a) using the Image J software. (c) DHM regulated the mRNA level of inflammatory response-induced insulin resistance-related genes was dependent on AMPK, as shown by qPCR. (d) DHM regulated the protein level of inflammatory response-induced insulin resistance-related genes was dependent on AMPK, as shown by WB. N = 6. **p < 0.01. Any two bars with different letters indicate that these two groups are statistically significantly different (p < 0.05). Magnification was 100x. The scale bar on the photomicrographs represents 50 μm.
Figure 4: Continued.
3.4. DHM Ameliorated the Inflammatory-Induced Insulin Resistance. We then investigated whether DHM prevented insulin resistance induced by the inflammatory response. DHM, less than 30 μM, did not damage cell viability based on MTT assay (Figure 2(a)). Insulin stimulation did not increase glucose uptake in 3T3-L1 cells after TNFα treatment (Figures 2(b) and 2(c)), while DHM prevented the TNFα-induced insulin resistance (Figures 2(b) and 2(c)). Compared with TNFα treatment, cotreatment with TNFα and DHM, AMPK was activated, and the expression of NF-κB and JNK was inhibited, as shown by qPCR and WB results (Figures 2(d) and 2(e) and Figure S4). Compared with TNFα treatment, DHM activated IRS-1 indicating that DHM ameliorated the TNFα-induced insulin resistance (Figures 2(d) and 2(e) and Figure S4). The improvement of insulin sensitivity, subsequently, increased the expression of GLUT4 (Figures 2(d) and 2(e) and Figure S4). Thus, the above results indicate that DHM ameliorated insulin resistance induced by inflammation.

3.5. DHM Ameliorated Inflammation-Induced Insulin Resistance through AMPK. We blocked AMPK activity using Compound C to investigate whether DHM exerted its anti-insulin resistance function through AMPK in 3T3-L1 cells. The ability of DHM to improve TNFα-induced insulin resistance was blocked by inhibiting AMPK, as shown by the glucose uptake assay (Figures 3(a) and 3(b)). When Compound C blocked AMPK activity, the activation effect of DHM on AMPK and IRS-1 disappeared (Figures 3(c) and 3(d) and Figure S5), and the promotion effect of DHM on the expression of GLUT4 also disappeared (Figures 3(c) and 3(d) and Figure S5). Blocked AMPK, DHM inhibitory effect on NF-κB and JNK was eliminated (Figures 3(c) and 3(d) and Figure S5). These results indicate that DHM ameliorated inflammation-induced insulin resistance in 3T3-L1 cells through AMPK.

3.6. DHM Ameliorated Inflammation-Induced Insulin Resistance through CaMKK-AMPK instead of LKB1-AMPK Pathway. We blocked the AMPK upstream factors CaMKK and LKB1 to investigate the pathway DHM used to activate AMPK. When STO-609 blocked CaMKK activity, the ability of DHM to improve TNFα-induced insulin resistance disappeared, as shown by the glucose uptake assay (Figures 4(a) and 4(b)). When STO-609 blocked CaMKK activity, the activation effect of DHM on CaMKK, AMPK, and IRS disappeared (Figures 4(c) and 4(d) and Figure S6B) and the promotion effect of DHM on the expression of GLUT4 also disappeared (Figures 4(c) and 4(d) and Figure S6B). Blocked CaMKK also caused DHM to lose its inhibitory effect on NF-κB and JNK (Figures 4(c) and 4(d) and Figure S6B). We then interfered with LKB1 expression using siRNA (Figures 4(e) and 4(f)). LKB1 interference did not affect the activation of AMPK by DHM (Figure 4(f) and Figure S6A). LKB1 interference did not affect the improvement of DHM on TNFα-induced insulin resistance, as shown by the glucose uptake assay.
These results indicate that DHM ameliorated inflammation-induced insulin resistance in 3T3-L1 cells through CaMKK-AMPK instead of the LKB1-AMPK pathway.

3.7. DHM Activated CaMKK by Increasing Intracellular Ca$^{2+}$ Concentration through the PLC-IP3 Receptor Pathway.

CaMKK is regulated by cellular Ca$^{2+}$, so we investigated whether DHM activated cellular Ca$^{2+}$ signal. DHM treatment activated intracellular Ca$^{2+}$ signal, as shown by the Ca$^{2+}$ probe test. When Ca$^{2+}$ was removed from the extracellular medium, DHM still increased intracellular Ca$^{2+}$ level (Figure 5(a)). After the cellular Ca$^{2+}$ was cleared by the intracellular Ca$^{2+}$ chelating agent BATAP-AM, the activation effect of DHM on intracellular Ca$^{2+}$ was eliminated, indicating that DHM activation on intracellular Ca$^{2+}$ was dependent on intracellular Ca$^{2+}$ storage (Figure 5(b)). After cellular Ca$^{2+}$ was cleared, DHM could no longer activate CaMKK, as shown by the WB results (Figure 5(c) and Figure S7A). Endoplasmic reticulum was the major organelle for Ca$^{2+}$ release and recovery in cells. We used U73122, a phospholipase C (PLC) inhibitor, to block the endoplasmic reticulum Ca$^{2+}$ channel IP3 receptor by preventing phospholipid phosphatidylinositol 4,5-diphosphate (PIP2) from degrading into inositol 1,4,5-triphosphate (IP3). We also used ryanodine to block the Ca$^{2+}$ channel ryanodine receptor. Blocking the ryanodine receptor did not affect cellular activation of intracellular Ca$^{2+}$ signal induced by DHM (Figure 5(d)). After the PLC-IP3 receptor pathway was blocked, the DHM function on

(Figures 4(g) and 4(h)).
Figure 6: Continued.
activating the intracellular Ca\textsuperscript{2+} signal disappeared (Figure 5(d)). After blocking the PLC-IP3 receptor pathway, DHM failed to activate CaMKK, as shown by the WB results (Figure 5(e) and Figure S7B). These results indicate that DHM activated CaMKK by increasing intracellular Ca\textsuperscript{2+} concentration through the PLC-IP3 receptor pathway.

### 3.8. DHM Ameliorated Inflammatory-Induced Insulin Resistance through Interaction with PLC

We verified the interaction of DHM and PLC by drug affinity responsive target stability (DARTS) assay to investigate the pathway DHM used to activate the PLC-IP3 receptor pathway. From the DARTS results, we found a brighter band at the position of about 50 KD SDS-PAGE gel in the DHM treatment group, suggesting that DHM might interact with the PLC (Figure 8(a)). At the same time, we also detected the DARTS product through WB. DHM promoted the stability of PLC protein, as shown by the WB results, indicating that DHM interacted with PLC protein (Figure 8(b) and Figure S8A). When U73122 blocked the PLC-IP3 receptor pathway, the activation effect of DHM on CaMKK, AMPK, and IRS-1 disappeared (Figure 8(c)), and the promotion effect of DHM on the expression of GLUT4 also disappeared (Figures 8(c) and 8(d) and Figure S8B). Blocked PLC-IP3 receptor pathway also caused DHM to lose its inhibitory effect on JNK and NF-κB (Figures 8(c) and 8(d) and Figure S8B). When U73122 blocked the PLC-IP3 receptor pathway, the ability of DHM to improve TNFα-induced insulin resistance disappeared, as shown by the glucose uptake assay (Figures 8(e) and 8(f)). These results indicate that DHM ameliorated inflammatory-induced insulin resistance through interaction with the PLC.

### 4. Discussion

Increasing incidence of metabolic syndrome-related diseases such as obesity, diabetes, and cardiovascular diseases has become a global health problem. Insulin resistance is the common pathophysiology basis of metabolic syndrome. All metabolic syndrome patients have insulin resistance in different degrees. Therefore, therapeutic strategies for metabolic syndrome need to ameliorate insulin resistance. In this study, we found that DHM activated the Ca\textsuperscript{2+}-CaMKK-AMPK signal pathway by binding to the PLC. Activation of AMPK ameliorated adipocytes insulin resistance by blocking the inflammation factor-induced inflammatory response. Our study not only clarified the molecular mechanism of DHM in inflammation-induced insulin resistance but also discovered the target of DHM in this process. This study offers a new therapeutic strategy for patients with metabolic syndrome.

The increasing incidence of insulin resistance is inextricably related to the increase in the global obese population [20]. A recent report showed that 2.1 billion people, about 30% of the world population, were either overweight or obese. During the process of obesity, the proliferation and hypertrophy of adipocytes triggered hypoxic stress, causing the secretion of inflammatory cytokines [21]. Our results showed that levels of serum and adipose tissue inflammatory cytokines were increased in HFD-induced obese mice.

The inflammatory cytokines secreted by adipose tissue activated NF-κB and JNK signal pathways in insulin-sensitive organs like adipose tissue, skeletal muscle, and liver [22–24]. The activation of NF-κB and JNK inhibited the phosphorylation of IRS-1 and, in turn, blocked the PI3K/AKT activation [25]. Results from our in vivo
experiments showed that the level of the inflammatory cytokines was increased in adipose tissue; the inflammatory cytokines induced the NF-κB and JNK-1 activation and insulin resistance in mice. Results from our in vitro experiments also showed that TNFα induced the NF-κB and JNK-1 activation and insulin resistance in 3T3-L1 cells.

AMPK is not only an important regulator in cellular energy metabolism but also plays an essential role in many physiological processes such as tumor growth, inflammation, and enhanced insulin sensitivity [26]. The pharmacological function of DHM to activate AMPK has been demonstrated in various physiological processes. DHM improved skeletal muscle insulin sensitivity partially through inducing autophagy by activating the AMPK-PPC-1α-Sirt signaling pathway [14]. DHM protected rats from developing Alzheimer’s disease via the upregulation of the AMPK-SIRT1 pathway to inhibit inflammation-induced apoptosis of hippocampal cells and ameliorate cognitive function [27]. We demonstrated that DHM activated AMPK in vivo and in vitro, and we also demonstrated that the function of DHM in ameliorating insulin resistance depended on its activation effect on AMPK in vitro.

AMPK blocked the inflammatory response by inhibiting the NF-κB signaling pathway. AMPK activation blocked the phosphorylation of IKK and NF-κB directly [28]. AMPK also activated SIRT1; then, P65, the subunit of NF-κB, was

**Figure 7:** DHM ameliorated inflammation-induced insulin resistance in HFD mice. (a) HFD elevated the level of adipose tissue inflammatory cytokines in mice, and DHM suppressed the effect of HFD. (b) Oral glucose tolerance test results showed that DHM improved HFD-induced insulin resistance. (c) HFD inhibited the mRNA level of AMPK, IRS-1, AKT, and GLUT4. DHM increased the mRNA level of NF-κB and JNK. DHM reversed the mRNA level of inflammation-induced insulin resistance-related genes. (d) HFD inhibited the protein level of p-AMPK, p-IRS-1, p-AKT, and GLUT4. DHM increased the protein level of p-NF-κB and JNK. DHM reversed the protein level of inflammation-induced insulin resistance-related genes. "p-" before the gene name means phosphorylated form. N = 6. Any two bars with different letters indicate that these two groups are statistically significantly different (p < 0.05).
Figure 8: Continued.
DHM promoted the stability of PLC protein, as shown by WB. (c) The effect of DHM on the mRNA level of inflammatory response-induced insulin resistance-related genes was dependent on the PLC-IP3 receptor pathway, as shown by qPCR. (d) The effect of DHM on the protein level of inflammatory response-induced insulin resistance-related genes was dependent on the PLC-IP3 receptor pathway, as shown by WB. "p-" before the gene name means phosphorylated form. (e) DHM alleviated TNFα-induced insulin resistance was dependent on the PLC-IP3 receptor pathway, as shown by the glucose uptake test. (f) Quantitative analysis of fluorescence intensity in (e) using the Image J software. N = 6. **p < 0.01. Any two bars with different letters indicate that these two groups are statistically significantly different (p < 0.05). Magnification was 100x. The scale bar on the photomicrographs represents 50 μm.

Figure 8: DHM (1 μM) ameliorated inflammatory-induced insulin resistance through interaction with PLC. (a) DHM might interact with the PLC, as shown by DARTS, and lines 1 to 5 represent molecular weight marker, DMSO, 10 nM DHM, and 1 μM DHM, respectively. (b) DHM promoted the stability of PLC protein, as shown by WB. The main storage organelle for Ca2+ is the endoplasmic reticulum. The ryanodine receptor and IP3 receptor are the main channels for calcium release from the endoplasmic reticulum and play a central role in cellular Ca2+ signal transduction [37]. In this study, we discovered that by blocking the PLC-IP3 receptor pathway, the DHM’s ability to activate Ca2+ and CaMKK disappeared, but blocking the ryanodine receptor had no effect on preventing the activation of Ca2+-CaMKK induced by DHM.

The identification of target protein for small molecules is critical for drug discovery and chemical metabolomics [38]. DARTS is a quick and straightforward approach to identify potential target protein of small molecules. The mechanism of DARTS is that the interaction of small molecule and target protein results in altered protein mobility. The most significant advantage of this method is it allows the use of the small native molecule without any modification, such as the incorporation of biotin, photoaffinity labels, or radioisotope [39]. In
this study, we used DARTS to identify potential binding targets of DHM and used DARTS-western blotting to test and validate the potential DHM target. Our results showed that DHM interacted with PLC to activate the Ca\(^{2+}\)-CaMKK-AMPK signal pathway.

5. Conclusion

In conclusion, our results not only showed that DHM ameliorated inflammation-induced insulin resistance but also demonstrated that DHM activated the Ca\(^{2+}\)-CaMKK-AMPK signal pathway through interacting with its target protein phospholipase C (Figure 9). Our results provided experimental data for the development of DHM as a functional food additive and a new therapeutic strategy for preventing insulin resistance.

Abbreviations

| Abbreviation | Definition                                      |
|--------------|------------------------------------------------|
| AKT          | Protein kinase B                                |
| DARTS        | Drug affinity responsive target stability       |
| DHM          | Dihydromyricetin                               |
| eWAT         | Epididymis white adipose tissue                |
| H&E          | Hematoxylin-eosin staining                     |
| HFD          | High-fat diet                                  |
| IP3          | Inositol 1,4,5-triphosphate                    |
| IRS          | Insulin receptor substrate                     |
| iWAT         | Inguinal white adipose tissue                  |
| JNK          | c-Jun NH2-terminal kinase                      |
| MTT          | Methyl thiazolyl diphenyl-tetrazolium bromide  |
| NF-κB        | Nuclear factor-kappa B                         |
| P13K         | Phosphatidylinositol 3-kinase                  |
| PIP2         | Phosphatidylinositol 4,5-diphosphate            |
| PLC          | Phospholipase C                                |
| TNFa         | Tumor necrosis factor α                         |

Data Availability

The data and materials supporting the conclusions are included within the article.

Ethical Approval

All experiments were conducted following “The Instructive Notions with Respect to Caring for Laboratory Animals” issued by the Ministry of Science and Technology of the People’s Republic of China. All experimental protocols and methods were approved by the College of Animal Science, South China Agricultural University.

Disclosure

The preprint of this article is submitted online [40].

Conflicts of Interest

The authors declare no conflict of interest.

Authors’ Contributions

Lianjie Hou contributed to the formal analysis, investigation, validation, visualization, writing—original draft, and writing—review and editing. Fangyi Jiang contributed to the formal analysis, investigation, and visualization. Bo Huang contributed to the formal analysis and investigation. Weijie Zheng contributed to the formal analysis and resources. Yufei Jiang contributed to the formal analysis and resources. Dewu Liu contributed to the funding acquisition. Gengyuan Cai contributed to the funding acquisition and writing—review and editing. Ching Yuan Hu contributed to the conceptualization, formal analysis, investigation, validation, visualization, and
writing—review and editing. Chong Wang contributed to the funding acquisition, investigation, project administration, resources, supervision, validation, visualization, and writing—review and editing. Lianjie Hou and Fangyi Jiang contributed equally to this study.

Acknowledgments

This work was supported by the Guangdong Provincial Key Area Research and Development Program (2018B020203002), the South China Agricultural University Major Project for International Science and Technology Cooperation Cultivation (2019SCAUGH01), and the Common Technical Innovation Team on Agricultural Seed Industry of Guangdong Province.

Supplementary Materials

Figure S1: DHM reversed the HFD-induced eWAT and iWAT hypertrophy. (A) The quantitative data of mouse adipose tissue weight. (B) The quantitative data of the adipocyte average area. N = 6. Any two bars with different letters indicate that these two groups are statistically significantly different (p < 0.05). Figure S2: grayscale scanning statistics of inflammatory-induced insulin resistance-related proteins in Figure 7(d). N = 6. Any two bars with different letters indicate that these two groups are statistically significantly different (p < 0.05). Figure S3: grayscale scanning statistics of inflammatory-induced insulin resistance-related proteins in Figure 1(e). N = 6. *p < 0.05 and **p < 0.01. Figure S4: grayscale scanning statistics of inflammatory-induced insulin resistance-related proteins in Figure 2(e). N = 6. Any two bars with different letters indicate that these two groups are statistically significantly different (p < 0.05). Figure S5: grayscale scanning statistics of inflammatory-induced insulin resistance-related proteins in Figure 3(d). N = 6. Any two bars with different letters indicate that these two groups are statistically significantly different (p < 0.05). Figure S6: statistical results related to Figure 4. (A) Grayscale scanning statistics of p-AMPK and LKB1 protein in Figure 4(f). (B) Grayscale scanning statistics of inflammatory-induced insulin resistance-related proteins in Figure 4(c). N = 6. Any two bars with different letters indicate that these two groups are statistically significantly different (p < 0.05). Figure S7: statistical results related to Figure 5. (A) Grayscale scanning statistics of p-CaMKK protein level in Figure 5(c). (B) Grayscale scanning statistics of p-CaMKK protein level in Figure 5(e). N = 6. Any two bars with different letters indicate that these two groups are statistically significantly different (p < 0.05). Figure S8: statistical results related to Figure 8. (A) Grayscale scanning statistics of PLC protein level in Figure 8(b). (B) Grayscale scanning statistics of inflammatory-induced insulin resistance-related protein level in Figure 8(d). N = 6. **p < 0.01. Any two bars with different letters indicate that these two groups are statistically significantly different (p < 0.05). (Supplementary Materials)

References

[1] J. P. Despres and I. Lemieux, “Abdominal obesity and metabolic syndrome,” Nature, vol. 444, no. 7121, pp. 881–887, 2006.
[2] S. M. Grundy, “Metabolic syndrome update,” Trends in cardiovascular medicine, vol. 26, no. 4, pp. 364–373, 2016.
[3] L. R. Aballay, A. R. Eynard, M. D. Diaz, A. Navarro, and S. E. Munoz, “Overweight and obesity: a review of their relationship to metabolic syndrome, cardiovascular disease, and cancer in South America,” Nutrition Reviews, vol. 71, no. 3, pp. 168–179, 2013.
[4] S. M. Alwahsh, B. J. Dwyer, S. Forbes, D. H. van Thiel, P. J. S. Lewis, and G. Ramadorni, “Insulin production and resistance in different models of diet-induced obesity and metabolic syndrome,” International Journal of Molecular Sciences, vol. 18, no. 2, p. 285, 2017.
[5] M. P. Czech, “Insulin action and resistance in obesity and type 2 diabetes,” Nature Medicine, vol. 23, no. 7, pp. 804–814, 2017.
[6] T. P. Patel, K. Rawal, A. K. Bagchi et al., “Insulin resistance: an additional risk factor in the pathogenesis of cardiovascular disease in type 2 diabetes,” Heart Failure Reviews, vol. 21, no. 1, pp. 11–23, 2016.
[7] N. Esser, S. Legrand-Poels, J. Piette, A. J. Scheen, and N. Paquot, “Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes,” Diabetes Research and Clinical Practice, vol. 105, no. 2, pp. 141–150, 2014.
[8] J. P. Bastard, M. Maachi, C. Lagathu et al., “Recent advances in the relationship between obesity, inflammation, and insulin resistance,” European Cytokine Network, vol. 17, no. 1, pp. 4–12, 2006.
[9] C. Guo, T. Huang, A. Chen et al., “Glucagon-like peptide 1 improves insulin resistance in vitro through anti-inflammation of macrophages,” Brazilian Journal of Medical and Biological Research, vol. 49, no. 12, p. e5826, 2016.
[10] G. Solinas, C. Vlccu, J. G. Neels et al., “JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity,” Cell Metabolism, vol. 6, no. 5, pp. 386–397, 2007.
[11] H. Tong, X. Zhang, L. Tan, R. Jin, S. Huang, and X. Li, “Multitarget and promising role of dihydromyricetin in the treatment of metabolic diseases,” European Journal of Pharmacology, vol. 870, article 172888, 2020.
[12] T. Liu, Y. Zeng, K. Tang, X. Chen, W. Zhang, and X. Xu, “Dihydromyricetin ameliorates atherosclerosis in LDL receptor deficient mice,” Atherosclerosis, vol. 262, pp. 39–50, 2017.
[13] X.-Y. Wan, L.-h. Gao, G.-h. Feng, Y. Zhang, X. Liu, and L. Li, “Effects of dihydromyricetin on insulin resistance in 3T3-L1 adipocytes and its mechanism,” Chinese Pharmacological Bulletin, vol. 30, no. 11, pp. 1580–1585, 2014.
[14] L. Shi, T. Zhang, Y. Zhou et al., “Dihydromyricetin improves skeletal muscle insulin sensitivity by inducing autophagy via the AMPK-PGC-1α-Sirt3 signaling pathway,” Endocrine, vol. 50, no. 2, pp. 378–389, 2015.
[15] J. He, J. Zhang, L. Dong et al., “Dihydromyricetin attenuates metabolic syndrome and improves insulin sensitivity by upregulating insulin receptor substrate-1 (Y612) tyrosine phosphorylation in db/db mice,” Diabetes Metabolic Syndrome and Obesity-Targets and Therapy, vol. 12, pp. 2237–2249, 2019.
[16] C. J. Hochstim, J. Y. Choi, D. Lowe, R. Masood, and D. H. Rice, “Biofilm detection with hematoxylin-eosin staining,” Archives of Otolaryngology – Head & Neck Surgery, vol. 136, no. 5, pp. 453–456, 2010.
[17] M. Y. Xie, L. J. Hou, J. J. Sun et al., “Porcine milk exosome MiRNAs attenuate LPS-induced apoptosis through inhibiting
TLR4/NF-κB and p53 pathways in intestinal epithelial cells,” *Journal of Agricultural and Food Chemistry*, vol. 67, no. 34, pp. 9477–9491, 2019.

[18] L. Hou, J. Shi, L. Cao, G. Xu, C. Hu, and C. Wang, "Pig has no uncoupling protein 1," *Biochemical and Biophysical Research Communications*, vol. 487, no. 4, pp. 795–800, 2017.

[19] B. Lomenick, R. Hao, N. Jonai et al., "Target identification using drug affinity responsive target stability (DARTS)," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, no. 51, pp. 21984–21989, 2009.

[20] S. Zhu, Z. Tian, D. Torioge et al., "Aging- and obesity-related peri-muscular adipose tissue accelerates muscle atrophy," *PLoS One*, vol. 14, no. 8, article e0221366, 2019.

[21] I. Alam, K. Lewis, J. Stephens, and J. Baxter, "Obesity, metabolic syndrome and sleep apnoea: all pro-inflammatory states," *Obesity Reviews : An Official Journal of the International Association for the Study of Obesity*, vol. 8, no. 2, pp. 119–127, 2007.

[22] M. Donath and S. Shoelson, "Type 2 diabetes as an inflammatory disease," *Nature Reviews. Immunology*, vol. 11, no. 2, pp. 98–107, 2011.

[23] R. Baker, M. Hayden, and S. Ghosh, "NF-κB, inflammation, and metabolic disease," *Cell Metabolism*, vol. 13, no. 1, pp. 11–22, 2011.

[24] H. Zhou, C. Urso, and V. Jadeja, "Saturated fatty acids in obesity-associated inflammation," *Journal of Inflammation Research*, vol. Volume 13, pp. 1–14, 2020.

[25] P. Dandona, A. Aljada, A. Chaudhuri, P. Mohanty, and R. Garg, "Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation," *Circulation*, vol. 111, no. 11, pp. 1448–1454, 2005.

[26] S. Herzig and R. Shaw, "AMPK: guardian of metabolism and mitochondrial homeostasis," *Nature Reviews. Molecular Cell Biology*, vol. 19, no. 2, pp. 121–135, 2018.

[27] P. Sun, J. Yin, L. Liu et al., "Protective role of Dihydromyricetin in Alzheimer’s disease rat model associated with activating AMPK/SIRT1 signaling pathway," *Bioscience Reports*, vol. 39, no. 1, 2019.

[28] C. Green, M. Pedersen, B. Pedersen, and C. Scheele, "Elevated NF-κB activation is conserved in human myocytes cultured from obese type 2 diabetic patients and attenuated by AMP-activated protein kinase," *Diabetes*, vol. 60, no. 11, pp. 2810–2819, 2011.

[29] F. Yeung, J. Hoberg, C. Ramsey et al., "Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase," *The EMBO Journal*, vol. 23, no. 12, pp. 2369–2380, 2004.

[30] J. Zhang, Y. Chen, H. Luo et al., "Recent update on the pharmacological effects and mechanisms of dihydromyricetin," *Frontiers in Pharmacology*, vol. 9, p. 1204, 2018.

[31] F. Ciccarese, E. Zulato, and S. Indraccolo, "LKB1/AMPK pathway and drug response in cancer: a therapeutic perspective," *Oxidative Medicine and Cellular Longevity*, vol. 2019, Article ID 8730816, 16 pages, 2019.

[32] S. Kim, Y. Y. Yoon, Y. W. Park, W. K. Whang, S. Y. Park, and K. W. Hwang, "Cynandione A from Cynanchum wilforii inhibits hepatic de novo lipogenesis by activating the LKB1/AMPK pathway in HepG2 cells," *Journal of natural medicines*, vol. 74, no. 1, pp. 142–152, 2020.

[33] X. Tong, K. A. Smith, and J. C. Pelling, "Apigenin, a chemopreventive bioflavonoid, induces AMP-activated protein kinase activation in human keratinocytes," *Molecular carcinogenesis*, vol. 51, no. 3, pp. 268–279, 2012.

[34] F. Zhao, W. W. Huang, Z. Zhang et al., "Triptolide induces protective autophagy through activation of the CaMKKK-AMPK signaling pathway in prostate cancer cells," *Oncotarget*, vol. 7, no. 5, pp. 5366–5382, 2016.

[35] H. Wang, X. Hu, M. Huang et al., "Mett13-mediated mRNA m^5A methylation promotes dendritic cell activation," *Nature Communications*, vol. 10, no. 1, p. 1898, 2019.

[36] A. Gerbino, D. Russo, M. Colella et al., "Dandelion root extract induces intracellular Ca^2+ increases in HEK293 cells," *International Journal of Molecular Sciences*, vol. 19, no. 4, p. 1112, 2018.

[37] T. Murayama and N. Kurebayashi, "Assays for modulators of ryanodine receptor (RyR)/Ca^{2+}/Ca^{2+} release channel activity for drug discovery for skeletal muscle and heart diseases," *Current Protocols in Pharmacology*, vol. 87, no. 1, article e71, 2019.

[38] A. McFedries, A. Schwaid, and A. Saghatelian, "Methods for the elucidation of protein-small molecule interactions," *Chemistry & Biology*, vol. 20, no. 5, pp. 667–673, 2013.

[39] M. Pai, B. Lomenick, H. Hwang et al., "Drug affinity responsive target stability (DARTS) for small-molecule target identification," *Methods in molecular biology*, vol. 1263, pp. 287–298, 2015.

[40] L. Hou, F. Jiang, B. Huang et al., "Dihydromyricetin ameliorates inflammation-induced insulin resistance via phospholipase C-CaMKK-AMPK signal pathway, 2020."